Medtronic plc
MDTAPI behind this page
MDT Q2 2026 request
Playground key active
/api/financials?ticker=MDT&year=2026&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Revenue | 8,961 | 8,403 | +6.6% |
Show Business Segments breakouts |
|||
| All Other Segments · Non Us | 13 | 19 | -31.6% |
| All Other Segments · Operating Segments | 35 | 37 | -5.4% |
| All Other Segments · US | 22 | 18 | +22.2% |
| Cardiovascular · Cardiac Rhythm & Heart Failure | 1,825 | 1,578 | +15.7% |
| Cardiovascular · Coronary & Peripheral Vascular | 655 | 643 | +1.9% |
| Cardiovascular · Non Us | 1,844 | 1,668 | +10.6% |
| Cardiovascular · Operating Segments | 3,436 | 3,102 | +10.8% |
| Cardiovascular · Structural Heart & Aortic | 956 | 881 | +8.5% |
| Cardiovascular · US | 1,592 | 1,434 | +11.0% |
| Diabetes · Non Us | 527 | 455 | +15.8% |
| Diabetes · Operating Segments | 757 | 686 | +10.3% |
| Diabetes · US | 230 | 232 | -0.9% |
| Medical Surgical · Acute Care & Monitoring | 493 | 478 | +3.1% |
| Medical Surgical · Non Us | 1,228 | 1,183 | +3.8% |
| Medical Surgical · Operating Segments | 2,171 | 2,128 | +2.0% |
| Medical Surgical · Surgical & Endoscopy | 1,679 | 1,649 | +1.8% |
| Medical Surgical · US | 943 | 944 | -0.1% |
| Neuroscience · Cranial & Spinal Technologies | 1,299 | 1,234 | +5.3% |
| Neuroscience · Neuromodulation | 520 | 480 | +8.3% |
| Neuroscience · Non Us | 832 | 774 | +7.5% |
| Neuroscience · Operating Segments | 2,562 | 2,451 | +4.5% |
| Neuroscience · Specialty Therapies | 744 | 737 | +0.9% |
| Neuroscience · US | 1,730 | 1,677 | +3.2% |
| Reportable segment net sales · Non Us | 4,432 | 4,080 | +8.6% |
| Reportable segment net sales · Operating Segments | 8,926 | 8,366 | +6.7% |
| Reportable segment net sales · US | 4,494 | 4,286 | +4.9% |
Show Geography breakouts |
|||
| IE | 35 | 29 | +20.7% |
| Non Us | 4,445 | 4,099 | +8.4% |
| Rest of world | 4,410 | 4,070 | +8.4% |
| Total other countries, excluding Ireland | 8,926 | 8,374 | +6.6% |
| US | 4,516 | 4,304 | +4.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 8,926 | 8,366 | +6.7% |
| Cost of Revenue | 3,061 | 2,946 | +3.9% |
Show Business Segments breakouts |
|||
| Cardiovascular · Operating Segments | 1,134 | 1,050 | +8.0% |
| Diabetes · Operating Segments | 316 | 288 | +9.7% |
| Medical Surgical · Operating Segments | 831 | 819 | +1.5% |
| Neuroscience · Operating Segments | 772 | 739 | +4.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 3,053 | 2,896 | +5.4% |
| Research And Development Expense Excluding Acquired In Process Cost | 754 | 697 | +8.2% |
Show Business Segments breakouts |
|||
| Cardiovascular · Operating Segments | 299 | 256 | +16.8% |
| Diabetes · Operating Segments | 108 | 109 | -0.9% |
| Medical Surgical · Operating Segments | 181 | 171 | +5.8% |
| Neuroscience · Operating Segments | 167 | 158 | +5.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 754 | 693 | +8.8% |
| Selling, General & Administrative | 2,965 | 2,757 | +7.5% |
Show Business Segments breakouts |
|||
| Cardiovascular · Operating Segments | 1,143 | 1,021 | +11.9% |
| Diabetes · Operating Segments | 279 | 266 | +4.9% |
| Medical Surgical · Operating Segments | 627 | 609 | +3.0% |
| Neuroscience · Operating Segments | 874 | 834 | +4.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,923 | 2,729 | +7.1% |
| Amortization Of Intangible Assets | 463 | 413 | +12.1% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 463 | 413 | +12.1% |
| Restructuring Charges Net Of Restructuring Reversals Including Cost Of Product Sold Impact | 10 | 30 | -66.7% |
| Other Operating Income Expense Net | 22 | -34 | +164.7% |
| Operating Income | 1,686 | 1,595 | +5.7% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 9 | 12 | -25.0% |
| Cardiovascular · Operating Segments | 877 | 781 | +12.3% |
| Diabetes · Operating Segments | 53 | 33 | +60.6% |
| Medical Surgical · Operating Segments | 531 | 525 | +1.1% |
| Neuroscience · Operating Segments | 740 | 725 | +2.1% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,201 | 2,065 | +6.6% |
| Other Non-Operating Income (Expense) | -92 | -173 | +46.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -92 | -173 | +46.8% |
| Interest Expense | 181 | 209 | -13.4% |
| Income Before Taxes | 1,597 | 1,559 | +2.4% |
| Income Tax Expense (Benefit) | 215 | 281 | -23.5% |
| Net Income | 1,381 | 1,278 | +8.1% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 7 | 9 | -22.2% |
| Parent | 1,374 | 1,270 | +8.2% |
| Retained Earnings | 1,374 | 1,270 | +8.2% |
| Net Income Loss Attributable To Noncontrolling Interest | -7 | -9 | +22.2% |
| Net Income | 1,374 | 1,270 | +8.2% |
| EPS (Basic) | 1.07 | 0.99 | +8.1% |
| EPS (Diluted) | 1.07 | 0.99 | +8.1% |
| Wtd Avg Shares (Basic) | 1,282 | 1,282.4 | -0.0% |
| Wtd Avg Shares (Diluted) | 1,288 | 1,286.9 | +0.1% |
| Comprehensive Income | 1,703 | 1,431 | +19.0% |
| Interest Income Expense Net | 89 | 137 | -35.0% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -47 | -37 | -27.0% |
Balance Sheet
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,282 | 1,394 | -8.0% |
| Short-Term Investments | 7,045 | 6,595 | +6.8% |
| Accounts Receivable | 6,389 | 6,260 | +2.1% |
| Inventory | 6,156 | 5,479 | +12.4% |
| Other Assets Current | 3,124 | 2,710 | +15.3% |
| Total Current Assets | 23,996 | 22,438 | +6.9% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 7,164 | 6,438 | +11.3% |
| Goodwill | 41,811 | — | — |
Show Business Segments breakouts |
|||
| Cardiovascular | 8,028 | — | — |
| Diabetes | 2,256 | — | — |
| Medical Surgical | 19,788 | — | — |
| Neuroscience | 11,738 | — | — |
| Deferred Tax Assets | 3,857 | 3,572 | +8.0% |
| Other Non-Current Assets | 3,748 | 4,009 | -6.5% |
| Total Assets | 91,346 | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 216 | — | — |
| Cardiovascular · Operating Segments | 16,663 | — | — |
| Diabetes · Operating Segments | 4,271 | — | — |
| Medical Surgical · Operating Segments | 32,984 | — | — |
| Neuroscience · Operating Segments | 18,479 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 18,732 | — | — |
| Operating Segments | 72,397 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 10,770 | 12,423 | -13.3% |
| Current Liabilities | |||
| Debt Current | 1,420 | 3,719 | -61.8% |
Show Short Term Debt Type breakouts |
|||
| Commercial Paper | 1.4 | 899 | -99.8% |
| Accounts Payable | 2,581 | 2,376 | +8.6% |
| Deferred Compensation Liability Current | 2,130 | 1,893 | +12.5% |
| Accrued Income Taxes Current | 650 | 947 | -31.4% |
| Other Liabilities Current | 3,153 | 3,260 | -3.3% |
| Total Current Liabilities | 9,935 | 12,195 | -18.5% |
| Non-Current Liabilities | |||
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 1,184 | 1,084 | +9.2% |
| Accrued Income Taxes Noncurrent | 1,539 | 1,432 | +7.5% |
| Deferred Tax Liabilities | 386 | 473 | -18.4% |
| Other Non-Current Liabilities | 1,764 | 1,534 | +15.0% |
| Total Liabilities | 42,489 | 41,326 | +2.8% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 0.375 percent eight-year 2020 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 0.750 percent twelve-year 2020 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 1.000 percent twelve-year 2019 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 1.125 percent eight-year 2019 senior notes · Senior Notes | 1,741 | 1,620 | +7.5% |
| 1.375 percent twenty-year 2020 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 1.500 percent twenty-year 2019 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 1.625 percent thirty-year 2020 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 1.625 percent twelve-year 2019 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 1.750 percent thirty-year 2019 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 2.950 percent five-year 2025 senior notes · Senior Notes | 870 | — | — |
| 3.000 percent six-year 2022 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 3.125 percent nine-year 2022 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 3.375 percent twelve-year 2022 senior notes · Senior Notes | 1,161 | 1,080 | +7.5% |
| 3.650 percent five-year 2024 senior notes · Senior Notes | 986 | 918 | +7.4% |
| 3.875 percent twelve-year 2024 senior notes · Senior Notes | 986 | 918 | +7.4% |
| 4.000 percent thirty-year 2013 senior notes · Senior Notes | 305 | 305 | 0.0% |
| 4.150 percent nineteen-year 2024 senior notes · Senior Notes | 696 | 648 | +7.4% |
| 4.150 percent twenty-nine-year 2024 senior notes · Senior Notes | 812 | 756 | +7.4% |
| 4.200 percent twenty-year 2025 senior notes · Senior Notes | 870 | — | — |
| 4.250 percent five-year 2023 senior notes · Senior Notes | 1,000 | 1,000 | 0.0% |
| 4.375 percent twenty-year 2015 senior notes · Senior Notes | 1,932 | 1,932 | 0.0% |
| 4.500 percent ten-year 2023 senior notes · Senior Notes | 1,000 | 1,000 | 0.0% |
| 4.500 percent thirty-year 2012 senior notes · Senior Notes | 105 | 105 | 0.0% |
| 4.625 percent thirty-year 2014 senior notes · Senior Notes | 127 | 127 | 0.0% |
| 4.625 percent thirty-year 2015 senior notes · Senior Notes | 1,813 | 1,813 | 0.0% |
| 5.550 percent thirty-year 2010 senior notes · Senior Notes | 224 | 224 | 0.0% |
| 6.500 percent thirty-year 2009 senior notes · Senior Notes | 158 | 158 | 0.0% |
| 6.550 percent thirty-year 2007 CIFSA senior notes · Senior Notes | 253 | 253 | 0.0% |
| Senior Notes 2019 Due 2039, 2.250 Percent [Member] · Senior Notes | 1,161 | 1,080 | +7.5% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 27,680 | 24,607 | +12.5% |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 20,857 | 20,824 | +0.2% |
| Retained Earnings | 32,070 | 30,919 | +3.7% |
| Accumulated Other Comprehensive Income | -4,275 | -3,250 | -31.5% |
| Total Stockholders' Equity | 48,652 | 48,494 | +0.3% |
| Minority Interest | 204 | — | — |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 48,857 | 48,716 | +0.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -638 | -529 | -20.6% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -108 | 139 | -177.7% |
| Accumulated Net Unrealized Investment Gain Loss | 11 | -101 | +110.9% |
| Accumulated Other Comprehensive Income | -4,275 | -3,250 | -31.5% |
| Accumulated Translation Adjustment | -2,740 | -3,468 | +21.0% |
| Additional Paid In Capital | 20,857 | 20,824 | +0.2% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent | -799 | 708 | -212.9% |
| Noncontrolling Interest | 204 | 222 | -8.1% |
| Parent | 48,652 | 48,494 | +0.3% |
| Retained Earnings | 32,070 | 30,919 | +3.7% |
| Total Liabilities & Equity | 91,346 | 90,042 | +1.4% |
Cash Flow Statement
| Metric | YTD Q2 2026 | YTD Q2 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 1,493 | 1,337 | +11.7% |
| Provision For Doubtful Accounts | 66 | 45 | +46.7% |
| Deferred Income Taxes And Tax Credits | 160 | 57 | +180.7% |
| Stock-Based Compensation | 268 | 242 | +10.7% |
| Other Non-Cash Items | 167 | -98 | +270.4% |
| Increase Decrease In Accounts And Notes Receivable | 74 | -181 | +140.9% |
| Change in Inventory | -672 | -278 | -141.7% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -780 | -707 | -10.3% |
| Increase Decrease In Other Operating Capital Net | -1,191 | -800 | -48.9% |
| Net Cash from Operations | 2,013 | 1,944 | +3.5% |
| Change in Deferred Revenue (YTD) | — | — | — |
Show Geography breakouts |
|||
| IT | 39 | — | — |
| Investing Activities | |||
| Capital Expenditures | -972 | -924 | -5.2% |
| Payments To Acquire Investments | -4,201 | -4,019 | -4.5% |
| Proceeds From Sale Maturity And Collections Of Investments | 3,958 | 4,338 | -8.8% |
| Other Investing Activities | 14 | 1 | +1300.0% |
| Net Cash from Investing | -1,201 | -604 | -98.8% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | 1,402 | -67 | +2192.5% |
| Proceeds From Issuance Of Long Term Debt | 1,747 | 3,209 | -45.6% |
| Repayments Of Long Term Debt | -2,930 | — | — |
| Payments Of Dividends Common Stock | -1,820 | -1,795 | -1.4% |
| Proceeds From Issuance Or Sale Of Equity | 255 | 232 | +9.9% |
| Share Repurchases | -495 | -2,780 | +82.2% |
| Proceeds From Payments For Other Financing Activities | 65 | -64 | +201.6% |
| Net Cash from Financing | -1,776 | -1,265 | -40.4% |
| Supplemental | |||
| Income Taxes Paid | 1,394 | 1,335 | +4.4% |
| Interest Paid | 542 | 513 | +5.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 28 | 35 | -20.0% |
| Net Change in Cash | -936 | 110 | -950.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,282 | 1,394 | -8.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.